Accelerate Your Small Molecule Drug Discovery With X-Chem
A leader in small molecule drug discovery and the DNA-encoded library (DEL) technology pioneer, X-Chem combines proven DEL and medicinal chemistry expertise with groundbreaking AI solutions. Unlock the power of your data and accelerate from hit-to-lead to candidate.
Our Latest Published Successes
Generate tangible, predictive insights with precision
HITMiner leverages high-resolution DEL data and our advanced AI platform, ArtemisAI, to uncover actionable molecular interactions and map compounds from any catalog with precision, enabling rapid hit expansion and informed decision-making.
What Our Clients Are Saying
“Our multi-year collaboration with X-Chem has been fruitful and has resulted in projects that have successfully progressed to include many high potential products.”
“We are excited to expand our collaboration with X-Chem, focusing on the synthesis and delivery of custom libraries as well as the transfer of the DEX™ platform in-house, an important pillar of our small molecule discovery strategy.”
“X-Chem’s approach to DEL libraries and screening complements Genentech’s small molecule drug discovery efforts and has the potential to help overcome long-standing challenges in drugging difficult oncology targets. We look forward to working with X-Chem to discover molecules that we hope could positively impact the lives of people with cancer.”
“With the cutting-edge technology offered by X-Chem and our knowledge of dermatology, we will be able to broaden our pipeline and provide further medical solutions for physicians and patients, specially designed for dermatological diseases with unmet needs.”
“We anticipate that our drug discovery research will be further enhanced through X-Chem’s breakthrough technology, leading to the creation of breakthrough pharmaceuticals.”
“As we tackle new targets, we have been very impressed with X-Chem’s technology platform and what it has delivered in the first 18 months of our partnership. Based on that success, we are eager to extend our work with X-Chem to additional targets for serious diseases.”
